Novartis gene therapy poised to expand SMA treatment landscape – Healthcare News
Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in...
Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in...
Novartis on Wednesday announced that the European Commission (EC) has approved Kisqali (ribociclib) for the treatment of early breast cancer...